HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9359 | Loncastuximab tesirine-lpyl | Zynlonta | 0.075mg | Immunotherapy | Drug Antibody Conjugate | CD19 | No | 2021 | Mar 25, 2022 | In Use | ||
S0116 | Bevacizumab | Avastin | 100 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jul 1, 2004 | Jun 30, 2006 | No Longer Used | |
Q5107 | Bevacizumab-awwb | Mvasi | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2018 | Jan 1, 2019 | In Use | ||
NA | Anagrelide | Agrylin | 0.5mg | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Yes | 1997 | In Use | |||
J9019 | Asparaginase | Erwinaze | 10, 000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2011 | Jan 1, 2013 | In Use | ||
Q5118 | Bevacizumab-bvzr | Zirabev | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2019 | Oct 1, 2019 | In Use | ||
Asciminib | Scemblix | 20mg,40mg | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Yes | 2021 | In Use | ||||
J9021 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn | Rylaze | 0.1mg | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2021 | Jan 26, 2022 | In Use | ||
NA | Avapritinib | Ayvakit | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
J9144 | Daratumumab, hyaluronidase-fihj | Darzalex Faspro | 10mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2020 | Jan 1, 2021 | In Use | ||
J9000 | Doxorubicin | Adriamycin | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1989 | Jan 1, 1984 | In Use | ||
Vorasidenib | Voranigo | 10mg,40mg | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Yes | 2024 | In Use | ||||
J9227 | Isatuximab-irtc | Sarclisa | 10mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2020 | Oct 1, 2020 | In Use | ||
NA | Avapritinib | Ayvakit | 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
NA | Lenalidomide | Revlimid | 5 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2005 | In Use | |||
J9056 | Bendamustine | Vivimusta | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | In Use | ||
J9058 | Bendamustine (Apotex) | Bendamustine (Apotex) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2023 | Jul 11, 2023 | In Use | ||
C9432 | Mitomycin | Mitosol | 5 mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | No | 1981 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
C9021 | Obinutuzumab | Gazyva | 10 mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2013 | Apr 4, 2014 | Dec 31, 2014 | No Longer Used | |
J0202 | Alemtuzumab | Lemtrada | 1 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | Jan 1, 2016 | In Use | ||
J9043 | Cabazitaxel | Jevtana | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2010 | Jan 1, 2012 | In Use | ||
C9295 | Carfilzomib | Kyprolis | 1 mg | Chemotherapy | Proteasome Inhibitor | 20S | No | 2012 | Jan 1, 2013 | Dec 31, 2013 | No Longer Used | |
J9047 | Carfilzomib | Kyprolis | 1 mg | Chemotherapy | Proteasome Inhibitor | 20S | No | 2012 | Apr 1, 2014 | In Use | ||
NA | Enasidenib mesylate | Idhifa | 100 mg | Chemotherapy | Enzyme Inhibitor | IDH2 | Yes | 2017 | In Use | |||
J9309 | Polatuzumab Vedotin | Polivy | 1mg | Immunotherapy | Drug Antibody Conjugate | CD79b | No | 2019 | Jan 1, 2020 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.